Loading... please wait

The 2023 Horizon Prize – MIT Solve Pitch Competition


Nadia Bodkin, Founder, Rare Advocacy Movement
Elisha Caleb, CEO, Agrotech Plus Ltd
Holly Copeland, Executive Director, CSR, Sustainability & Impact, Horizon Therapeutics
Rachael Drew, Portfolio Lead, MIT Solve
Peter Fish, CEO, Mendelian
Claudia Lorena Garcia, Senior Consultant, TriCiclos Colombia
Vikram Karnani, EVP & President, Global Commercial Operations and Medical Affairs, Horizon Therapeutics
Kevin Keaton, Founding Partner, Red Cell Partners
William Mapham, CEO, Vula
Noryawati Mulyono, CEO, PT Seaweedtama Biopac Indonesia
Sheetal Rao, Assistant Professor of Clinical Medicine, Nordson Green Earth Foundation (NGEF)
Rohit Sahgal, Director, Sovereign Health Singapore
Eda Selebatso, Founder & Chairperson, Botswana Organisation for Rare Diseases
Catharine Smith, Executive Director, Termeer Foundation
Jeni Stockman, Senior Deployment Manager, Pendulum Systems
Durhane Wong-Rieger, President & CEO, Canadian Organization for Rare Disorders


With patron Programming sponsor

2560px Horizon Therapeutics logo.svg - The 2023 Horizon Prize - MIT Solve Pitch Competition

We have manufactured seaweed-based biopackaging since 2020 to replace single-use plastic.”

– Noryawati Mulyono 

We are applying and processing billions of clinical records and clinical events to identify one of 40 of the hardest to diagnose rare diseases.”

– Peter Fish

“We create hope for every person suffering from rare diseases and we are bringing hope to our rural community.”

– Elicia Caleb

Our solutions learn from existing data to predict demand and allocate with precision so that resources go where they are needed with far less waste.”

– Jeni Stockman

“Most healthcare records for patients with rare diseases in Africa are still on paper. And you can’t save the world with AI if there’s no data. So we have to find a way to make the data visible.”

– Dr. William Mapham

Key takeaways & next steps:

  • The 2023 Horizon Prize for Rare Diseases, a collaboration between MIT Solve and Horizon Therapeutics, aims to find tech-based solutions to alleviate challenges faced by rare disease families, honoring Vula Mobile for linking healthcare workers in Ghana to reduce diagnostic journeys and emissions, and Mendelian for their artificial intelligence (AI) technology MandelScan, identifying rare diseases through health records in the NHS.
  • Noryawati Mulyono, Co-Founder of PT Seaweedtama Biopac Indonesia, creates seaweed-based biodegradable medical products to reduce plastic waste in the medical device sector as well as reducing ocean acidification through seaweed farming.
  • Peter Fish, CEO of Mendelian, is developing a software as a medical device (AI-driven) called MendelScan. This software utilizes electronic health records to identify patients who may have undiagnosed rare diseases, potentially accelerating the diagnosis process and improving health equity for rare disease patients.
  • Elicia Caleb, CEO of Change Your Box, uses solar-powered cooling technology to extend the shelf life of medical supplies, with a primary goal of improving access to healthcare services, treatments, and vaccines in rural and remote communities.
  • Jeni Stockman, Sr Deployment Manager of Pendulum, leverages AI and machine learning to optimize healthcare supply chains, reducing waste, improving access, and decreasing carbon emissions by predicting demand and efficiently allocating resources.
  • Dr. William Mapham, CEO of Vula Health, connects healthcare workers, including specialists, to enhance healthcare access in underserved regions, addressing challenges like cost, access, and transportation barriers for patients with rare diseases.